|View printer-friendly version|
|July 05, 2016 11:01 a.m.|
|Teva and the Huntington Study Group Announce Publication of Pivotal Phase III Data on Deutetrabenazine (SD-809) in Huntington Disease from First-HD Trial in JAMA|
“We are proud to have the First-HD results published in JAMA,”
“As a physician who cares for people with HD, it’s gratifying to see
positive results from a well-designed, fully enrolled trial. Until we
find a cure, we aim to bring our patients more treatment options to
relieve symptoms,” said Dr.
For more information regarding this JAMA publication, visit http://jama.jamanetwork.com/issue.aspx.
About SD-809 (deutetrabenazine) Tablets
SD-809 (deutetrabenazine) is an investigational, oral, small-molecule
inhibitor of vesicular monoamine 2 transporter, or VMAT2, that is being
developed for the treatment of chorea associated with Huntington disease
(HD). Deutetrabenazine has been granted Orphan Drug Designation for the
treatment of HD by the
About Huntington Disease
Huntington disease (HD) is a fatal neurodegenerative disease characterized by uncoordinated and uncontrollable movements, cognitive deterioration and behavioral and/or psychological problems. Onset of HD symptoms typically occurs in middle age, but the disease also manifests in children and the elderly. HD is the most common genetic cause of abnormal involuntary writhing movements called chorea.
Teva's Safe Harbor Statement under the
This release contains forward-looking statements, which are based on
management’s current beliefs and expectations and involve a number of
known and unknown risks and uncertainties that could cause our future
results, performance or achievements to differ significantly from the
results, performance or achievements expressed or implied by such
forward-looking statements. Important factors that could cause or
contribute to such differences include risks relating to: our ability to
develop and commercialize additional pharmaceutical products;
competition for our specialty products, especially Copaxone® (which
faces competition from orally-administered alternatives and a generic
version); our ability to consummate the acquisition of
Teva Pharmaceutical Industries Ltd.